Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE):...

por Swain, S M, Ewer, M S, Viale, G, Delaloge, S, Ferrero, J -M, Verrill, M, Colomer, R, Vieira, C, Werner, T L, Douthwaite, H, Bradley, D, Waldron-Lynch, M, Kiermaier, A, Eng-Wong, J, Dang, C
Publicado 2018

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

por de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J.M., Frank, E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M.S., Dent, S., Plummer, C., Suter, T.
Publicado 2023